Reference
HPRA. Xeljanz (tofacitinib) - Important Safety Information from Pfizer Healthcare Ireland as approved by the HPRA (July 2021) Internet Document : 12 Jul 2021. Available from: URL: https://www.hpra.ie/homepage/medicines/safety-notices/item?t=/xeljanz-(tofacitinib)---important-safety-information-from-pfizer-healthcare-ireland-as-approved-by-the-hpra-(july-2021)&id=99e90f26-9782-6eee-9b55-ff00008c97d0
Rights and permissions
About this article
Cite this article
Tofacitinib increases risk of MI, lung cancer and lymphoma. Reactions Weekly 1865, 6 (2021). https://doi.org/10.1007/s40278-021-99294-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-99294-y